It’s been a crucial week for ChemoCentryx, Inc. (NASDAQ:CCXI); here’s what analysts have to say.

March 16, 2018 - By Richard Conner

 It's been a crucial week for ChemoCentryx, Inc. (NASDAQ:CCXI); here's what analysts have to say.
Investors sentiment decreased to 1.14 in Q3 2017. Its down 0.26, from 1.4 in 2017Q2. It dived, as 12 investors sold ChemoCentryx, Inc. shares while 23 reduced holdings. 12 funds opened positions while 28 raised stakes. 23.75 million shares or 2.21% less from 24.29 million shares in 2017Q2 were reported.
Federated Incorporated Pa has 64,610 shares for 0% of their portfolio. Strs Ohio has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Spark Mngmt Ltd Liability Com invested 0.07% in ChemoCentryx, Inc. (NASDAQ:CCXI). Nantahala Cap Mngmt Limited Company reported 0.25% stake. Northern Tru owns 275,945 shares or 0% of their US portfolio. Paw Cap Corp accumulated 160,000 shares. Prelude Mgmt Limited Com stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). California State Teachers Retirement System, California-based fund reported 38,082 shares. Los Angeles Capital Management & Equity Research Incorporated has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Arrowstreet Partnership holds 17,999 shares. Renaissance Technology Ltd holds 0.01% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI) for 926,881 shares. Sei Investments Com holds 0% or 2,329 shares in its portfolio. California-based Schwab Charles Inv Mngmt has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Proshare Lc has invested 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Artal Group reported 500,000 shares or 0.06% of all its holdings.

ChemoCentryx, Inc. (NASDAQ:CCXI) Ratings Coverage

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. ChemoCentryx had 6 analyst reports since September 3, 2015 according to SRatingsIntel. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) earned “Buy” rating by JMP Securities on Thursday, August 10. The rating was downgraded by Zacks on Thursday, September 3 to “Sell”. On Tuesday, August 8 the stock rating was maintained by Cowen & Co with “Hold”. The rating was maintained by JP Morgan on Tuesday, March 13 with “Overweight”. The stock of ChemoCentryx, Inc. (NASDAQ:CCXI) has “Mkt Outperform” rating given on Tuesday, February 21 by JMP Securities. The rating was downgraded by Zacks to “Sell” on Monday, September 21. Below is a list of ChemoCentryx, Inc. (NASDAQ:CCXI) latest ratings and price target changes.

13/03/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $13 New Target: $16 Maintain

The stock increased 2.09% or $0.29 during the last trading session, reaching $14.14. About 354,722 shares traded or 25.92% up from the average. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 60.64% since March 16, 2017 and is uptrending. It has outperformed by 43.94% the S&P500.

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, develops medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company has market cap of $689.56 million. The Company’s lead drug candidate is Avacopan , an orally-administered small molecule that is a selective inhibitor of the complement C5a receptor (C5Ar), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV). It has a 39.28 P/E ratio. The firm also engages in developing CCX140, an inhibitor of the chemokine receptor known as CCR2 for patients with focal segmental glomerulosclerosis (FSGS), a debilitating kidney disease; Vercirnon for the treatment of patients with moderate-to-severe CrohnÂ’s diseases; CCX872, a selective inhibitor of the human CCR2 that has completed Phase I clinical trial for the treatment of pancreatic cancer; CCX507, which has completed Phase I clinical trial for the treatment of inflammatory bowel diseases; and Th17 cells for the treatment of psoriasis, rheumatoid arthritis, asthma, and multiple sclerosis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.